Phase 1 study of recombinant human CD4-immunoglobulin G therapy of patients with AIDS and AIDS-related complex

The safety and pharmacokinetics of recombinant CD4-immunoglobulin G (rCD4-IgG) were evaluated in a phase 1 study with dose escalation. A total of 16 patients, 6 with AIDS and 10 with AIDS-related complex, were evaluated at two university-affiliated hospital clinics. rCD4-IgG was administered once weekly for 12 weeks to four patients each at doses of 0.03, 0.1, 0.3, and 1.0 mg/kg of body weight. Dosing was intravenous for two patients in the 1.0-mg/kg dose group and intramuscular for the remaining patients. Dosing was intravenous for two patients in the 1.0-mg/kg dose group and intramuscular for the remaining patients. Pharmacokinetic, toxicity, and immunologic variables were monitored with all patients. Administration of rCD4-IgG was well tolerated, with no important clinical or immunologic toxicities noted. No subjects required dose reduction or discontinuation of therapy due to toxicity. No consistent changes were seen in human immunodeficiency virus antigen levels in serum or CD4 lymphocyte populations. The volume of distribution was small, and compared with that of rCD4, the half-life of the hybrid molecule was markedly prolonged following intramuscular or intravenous administration. The rate and extent of absorption following intramuscular dosing were variable. Intramuscular administration of rCD4-IgG appears to be inferior to intravenous dosing from a pharmacokinetic standpoint, with lower peak concentrations and variable absorption. After intravenous administration, peak concentrations of rCD4-IgG in serum (20 to 24 micrograms/ml) that have shown antiviral activity in vitro against more sensitive clinical isolates of human immunodeficiency virus were achieved. The peak concentrations in serum after intramuscular administration were below these levels. Treatment with rCD4-IgG was well tolerated at the doses administered to patients in this study but did not result in significant changes in CD4 lymphocyte counts or p24 antigen levels in serum.

[1]  J. Mordenti,et al.  Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin , 1991, Nature.

[2]  M. Spellman,et al.  Structural characterization of a recombinant CD4-IgG hybrid molecule. , 1990, European journal of biochemistry.

[3]  M. Hirsch,et al.  Three-drug synergistic inhibition of HIV-1 replication in vitro by zidovudine, recombinant soluble CD4, and recombinant interferon-alpha A. , 1990, The Journal of infectious diseases.

[4]  F. Wurm,et al.  Biological properties of a CD4 immunoadhesin , 1990, Nature.

[5]  J. Groopman,et al.  Characterization of in vitro inhibition of human immunodeficiency virus by purified recombinant CD4 , 1989, Journal of virology.

[6]  D. Lamarre,et al.  The MHC-binding and gp120-binding functions of CD4 are separable. , 1989, Science.

[7]  K. Karjalainen,et al.  Highly efficient neutralization of HIV with recombinant CD4-immunoglobulin molecules , 1989, Nature.

[8]  N. Letvin,et al.  Effect of recombinant soluble CD4 in rhesus monkeys infected with simian immunodeficiency virus of macaques , 1989, Nature.

[9]  Q. Sattentau,et al.  The human and simian immunodeficiency viruses HIV-1, HIV-2 and SIV interact with similar epitopes on their cellular receptor, the CD4 molecule. , 1988, AIDS.

[10]  B. Walker,et al.  HIV infection is blocked in vitro by recombinant soluble CD4 , 1988, Nature.

[11]  S. Marsters,et al.  Blocking of HIV-1 infectivity by a soluble, secreted form of the CD4 antigen. , 1987, Science.

[12]  Eric O Long,et al.  Functional interaction between human T-cell protein CD4 and the major histocompatibility complex HLA-DR antigen , 1987, Nature.

[13]  A J Langlois,et al.  Human T-cell lymphotropic virus IIIB glycoprotein (gp120) bound to CD4 determinants on normal lymphocytes and expressed by infected cells serves as target for immune attack. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  Robin A. Weiss,et al.  The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain , 1986, Cell.

[15]  A. Jones,et al.  A sensitive radioimmunoprecipitation assay for the detection of antibody to recombinant human gamma-interferon: comparison to a bioassay neutralization test. , 1986, Journal of interferon research.

[16]  J K Nicholson,et al.  Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. , 1986, Science.

[17]  A. Fauci,et al.  Immunologic abnormalities in the acquired immunodeficiency syndrome. , 1985, Annual review of immunology.

[18]  Luc Montagnier,et al.  T-lymphocyte T4 molecule behaves as the receptor for human retrovirus  LAV , 1984, Nature.

[19]  M. Greaves,et al.  The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus , 1984, Nature.